End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.35 CNY | -18.75% | -15.81% | -45.40% |
10:12am | Hainan Poly Pharm Gets GMP Certificate From Saudi Authorities | MT |
04-08 | Hainan Poly Pharm Gets Nod to Market Voriconazole Injection in Sweden | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- With a P/E ratio at 11.6 for the current year and 9.96 for next year, earnings multiples are highly attractive compared with competitors.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-45.40% | 765M | C- | ||
+31.37% | 662B | C+ | ||
+21.96% | 546B | B | ||
-5.32% | 359B | C+ | ||
+17.02% | 323B | B- | ||
+4.70% | 289B | C+ | ||
+13.68% | 234B | B+ | ||
+3.81% | 198B | B- | ||
-10.63% | 194B | A+ | ||
+4.12% | 167B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300630 Stock
- Ratings Hainan Poly Pharm. Co., Ltd